There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amgen (AMGN – Research Report), Bausch Health Companies (BHC – Research Report) and Ultragenyx Pharmaceutical (RARE – Research Report) with bullish sentiments.
Amgen (AMGN)
Jefferies analyst Michael Yee maintained a Buy rating on Amgen today and set a price target of $375.00. The company’s shares closed last Tuesday at $270.36.
According to TipRanks.com, Yee is a 1-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $312.67, representing a 15.7% upside. In a report issued on April 3, RBC Capital also maintained a Buy rating on the stock with a $329.00 price target.
See the top stocks recommended by analysts >>
Bausch Health Companies (BHC)
In a report released today, Glen Santangelo from Jefferies maintained a Buy rating on Bausch Health Companies, with a price target of $16.00. The company’s shares closed last Tuesday at $9.26.
According to TipRanks.com, Santangelo is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Bausch Health Companies with a $10.50 average price target.
Ultragenyx Pharmaceutical (RARE)
Jefferies analyst Maury Raycroft maintained a Buy rating on Ultragenyx Pharmaceutical today and set a price target of $129.00. The company’s shares closed last Tuesday at $50.56.
According to TipRanks.com, Raycroft is a 4-star analyst with an average return of
Currently, the analyst consensus on Ultragenyx Pharmaceutical is a Strong Buy with an average price target of $90.07, a 78.9% upside from current levels. In a report issued on April 3, Leerink Partners also maintained a Buy rating on the stock with a $98.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMGN:
- Amgen shares worth $240-$250 without obesity pipeline, says JPMorgan
- AMGEN ANNOUNCES 2024 SECOND QUARTER DIVIDEND
- Amgen upgraded to Conviction Buy from Buy at Goldman Sachs
- Jefferies biotechnology analyst to hold an analyst/industry conference call
- Amgen opens state-of-the-art biomanufacturing facility in central Ohio
